Document Detail

Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2.
MedLine Citation:
PMID:  22681725     Owner:  NLM     Status:  MEDLINE    
Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome with a prevalence of approximately 1 in 30,000. NF 2 is characterized by bilateral vestibular schwannomas, as well as meningiomas, ependymomas and gliomas. Currently, surgical resection and radiotherapy represent the mainstay of treatment, although new studies suggest a role for certain chemotherapeutic agents. Intravenous administration of Bevacizumab (Avastin, Genetech Pharmaceuticals) has been shown to be active in the treatment of vestibular schwannomas. The IV route of administration, however, carries a risk of known systemic side-effects such as bowel perforation, wound dehiscence and pulmonary embolism. In addition, the percentage of drug that reaches the tumor site may be restricted by the blood tumor barrier. This report describes the super-selective intra-arterial infusion of Bevacizumab following blood brain barrier disruption for the treatment of vestibular schwannomas in three patients with Neurofibromatosis type 2. It represents the first time such a technique has been performed for this disease. Additionally, this method of drug delivery may have important implications in the treatment of patients with vestibular schwannomas associated with Neurofibromatosis type 2.
H A Riina; J-K Burkhardt; A Santillan; L Bassani; A Patsalides; J A Boockvar
Related Documents :
22814425 - Micrornas and aneurysm formation.
22344985 - The midterm experience of tapered stent grafts in the endovascular management of iliac ...
22436545 - Endoscopic vascular harvest in coronary artery bypass grafting surgery: a consensus sta...
3383725 - Pulmonary and systemic vascular effects of serotonin in conscious newborn lambs.
23411835 - Bentall operation for prosthetic valve endocarditis with hereditary hemorrhagic telangi...
4012555 - Angiographic classification of aneurysms of the horizontal segment of the anterior cere...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-06-04
Journal Detail:
Title:  Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences     Volume:  18     ISSN:  1591-0199     ISO Abbreviation:  Interv Neuroradiol     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-11     Completed Date:  2012-09-20     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  9602695     Medline TA:  Interv Neuroradiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  127-32     Citation Subset:  IM    
Department of Neurosurgery, New York University Langone Medical Center, New York, NY 10016, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Angiography, Digital Subtraction
Antibodies, Monoclonal, Humanized / administration & dosage*
Blood-Brain Barrier
Cerebral Angiography
Infusions, Intra-Arterial
Magnetic Resonance Angiography
Middle Aged
Neurofibromatosis 2 / complications*
Neuroma, Acoustic / drug therapy*,  etiology*
Treatment Outcome
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose...
Next Document:  Preoperative embolization of meningiomas with N-butyl cyanoacrylate.